Improving treatment of advanced melanoma may require the development of effective strategies to overcome resistance to different anti-tumor agents and to counteract relevant pro-tumoral mechanisms in the microenvironment. Here we provide preclinical evidence that these goals can be achieved in most melanomas, by co-targeting of oncogenic and death receptor pathways, and independently of their BRAF, NRAS, p53 and PTEN status. In 49 melanoma cell lines, we found independent susceptibility profiles for response to the MEK1/2 inhibitor AZD6244, the PI3K/mTOR inhibitor BEZ235 and the death receptor ligand TRAIL, supporting the rationale for their association. Drug interaction analysis indicated that a strong synergistic anti-tumor activity could be achieved by the three agents and the AZD6244-TRAIL association on 20/21 melanomas, including cell lines resistant to the inhibitors or to TRAIL. Mechanistically, synergy was explained by enhanced induction of caspase-dependent apoptosis, mitochondrial depolarization and modulation of key regulators of extrinsic and intrinsic cell death pathways, including c-FLIP, BIM, BAX, clusterin, Mcl-1 and several IAP family members. Moreover, silencing experiments confirmed the central role of Apollon downmodulation in promoting the apoptotic response of melanoma cells to the combinatorial treatments. In SCID mice, the AZD6244-TRAIL association induced significant growth inhibition of a tumor resistant to TRAIL and poorly responsive to AZD6244, with no detectable adverse events on body weight and tissue histology. Reduction in tumor volume was associated not only with promotion of tumor apoptosis but also with suppression of the pro-angiogenic molecules HIF1α, VEGFα, IL-8 and TGFβ1 and with inhibition of tumor angiogenesis. These results suggest that synergistic co-targeting of oncogenic and death receptor pathways can not only overcome melanoma resistance to different anti-tumor agents in vitro but can also promote pro-apoptotic effects and inhibition of tumor angiogenesis in vivo.
The development of mutant BRAF (v-raf murine sarcoma viral oncogene homolog B)-and mitogen/extracellular signalregulated kinase (MEK)-specific inhibitors, such as Vemurafenib, Dabrafenib and Trametinib, as well as of monoclonal antibodies targeting immune checkpoints, has markedly improved the treatment of advanced melanoma, as shown by highly significant effects, achieved in several trials, on progression-free and/or overall survival. [1] [2] [3] [4] [5] However, a fraction of patients does not benefit from target-specific therapy or immunotherapy, and duration of clinical responses may be limited. [1] [2] [3] [4] [5] Mechanisms of resistance to specific inhibitors 6 and of tumor escape from immune recognition 7 contribute to prevent induction of melanoma cell death by the new therapies and explain the urgent need for the identification of more effective approaches. Different strategies are being investigated to overcome melanoma resistance to single anti-tumor agents and to rescue tumor susceptibility to cell death, including co-targeting of constitutively active intracellular signaling pathways, [8] [9] [10] association of target-specific drugs with inhibitors of autophagy or with endoplasmic reticulumstress inducers 11, 12 and association of anti-tumor agents that trigger the extrinsic and the intrinsic pathway of apoptosis. [13] [14] [15] The latter approach is based on the combination of specific inhibitors of main oncogenic pathways, which in different tumor types can modulate relevant pro-and anti-apoptotic molecules in the intrinsic pathway of cell death, [16] [17] [18] with targeting of the extrinsic, death receptor-dependent pathway, by usage of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or of agonistic death receptor 5 (DR5)-specific mAbs. 19 Indeed, this approach has shown that association of MEK, pan-RAF or phosphoinositide 3-kinase (PI3K) inhibitors with TRAIL can overcome resistance to TRAIL [13] [14] [15] and can lead to enhanced melanoma apoptosis in vitro through different mechanisms, including upregulation of bcl-2-like protein 11 isoform 1 (Bim) and activation of BCL2associated X protein (Bax). [13] [14] [15] Moreover, as hypothesized recently by Geserick et al., 20 the association of MEK or pan-RAF inhibitors with TRAIL could even be exploited as a potential approach to promote rapid elimination of most tumor cells, thus preventing the emergence of secondary resistance to BRAF inhibitors. Furthermore, the interest in the death receptor pathway, as a therapeutic target, has been recently strengthened by the evidence that TRAIL mediates disruption of the tumor-associated vasculature 21 and by the discovery of TIC10, a drug that stimulates production of TRAIL and that exerts significant anti-tumor activities in preclinical in vivo models, including aggressive intracranial xenografts of human glioblastoma cells. 22 Nevertheless, it is currently not known whether co-targeting of MEK and/or PI3K/mammalian target of rapamycin (mTOR) and of the death receptor pathway in melanoma can overcome intrinsic resistance to each of the anti-tumor agents in most instances, irrespective of the different genetic make-up of the tumors, and whether this approach can exert synergistic, rather than additive, anti-melanoma effects. Furthermore, it remains to be verified whether the combination of MEK or PI3K/mTOR inhibitors with death receptor agonists (such as TRAIL itself or DR5-specific mAbs) may also exert significant pro-apoptotic effects in vivo on melanoma xenografts and whether this is associated with inhibition of relevant protumoral processes in the tumor microenvironment.
To address these issues, in this study we evaluated the antimelanoma activity in vitro and in vivo of two-or three-drug associations using TRAIL, the MEK 1/2 inhibitor AZD6244/ Selumetinib, which has significant clinical activity in melanoma, 23 and the PI3K/mTOR inhibitor BEZ235, currently in clinical trials in different solid tumors, including melanoma (source www.clinicaltrials.gov). The results indicated that the three-agent (AZD6244/BEZ235/TRAIL) and two-agent (AZD6244/TRAIL) combinations exerted synergistic proapoptotic effects on most melanomas in a large panel. These results were observed even on melanoma cell lines resistant to TRAIL or to the inhibitors and independently of their BRAF, neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), p53 and phosphatase and tensin homolog (PTEN) status. Moreover, an in vivo model showed that the AZD6244/TRAIL association promoted melanoma apoptosis associated with marked inhibition of angiogenesis.
Results
Independent susceptibility profiles to target-specific inhibitors and TRAIL in human melanomas. We asked whether concomitant resistance to MEK, PI3K/mTOR inhibitors and to the death receptor ligand TRAIL is frequent in human melanoma. To this end, a panel of 49 melanoma cell lines ( Supplementary Table S1 ), with known BRAF, NRAS, PTEN and p53 status, was characterized for susceptibility to AZD6244, BEZ235 and TRAIL. Several lines responsive (IC 50 o0.05 μM) to AZD6244 or BEZ235 were TRAIL resistant (o10% dead cells at TRAIL 100 ng/ml), whereas a number of cell lines resistant to these inhibitors (IC 50 ≥ 0.2 μM) showed good susceptibility to TRAIL (representative data in Figure 1a ). Spearman analysis of raw data shown in Supplementary Table S1 indicated no significant correlation between susceptibility to the inhibitors and to TRAIL ( Figure 1b ). Indeed, concomitant resistance to AZD6244 and TRAIL or to BEZ235 and TRAIL was found in only 7 and 10 cell lines, respectively (marked by open circles and squares, Figure 1b ), supporting the rationale for association of these anti-tumor agents. We then found that response to TRAIL correlated significantly not only with caspase-8 cleavage (P = 0.0086) but even with mitochondrial depolarization (Po0.0001, Figure 1b and Supplementary Table S1 ), in agreement with the notion that melanoma cells behave as type II cells in response to TRAIL, requiring activation of the intrinsic pathway of cell death. 24 This latter finding provided also a mechanistic rationale for the co-targeting of oncogenic and death receptor pathways. In fact, TRAIL triggers the extrinsic pathway of apoptosis, while inhibitors, such as AZD6244 or BEZ235, can promote cell death by modulating pro-and anti-apoptotic molecules in the intrinsic pathway of cell death. [16] [17] [18] In addition, TRAIL-R1 (DR4) and TRAIL-R2 (DR5) were always expressed in vitro, although with different staining intensity (Supplementary Figure S1a) , and the levels of expression of DR5 correlated significantly with responsiveness to TRAIL, indicating the relevance of such receptor (Supplementary Figure S1a) . In vivo TRAIL-R2/DR5 expression was confirmed in neoplastic cells from melanoma metastases (Supplementary Figure S1b ), supporting the choice of targeting this pathway in melanoma.
Co-targeting of oncogenic and death receptor pathways exerts synergistic anti-tumor effects in most melanomas, irrespective of genetic background, and overcomes resistance to each agent. Melanoma cell lines susceptible to AZD6244, BEZ235 and TRAIL (Me1 and Me83) or resistant to TRAIL and poorly responsive to AZD6244 (Me13 and Me6) were selected for drug interaction analysis. All possible two-and three-drug combinations were evaluated by the Chou and Talalay method. 25 Outcome of drug interaction, in terms of synergism/antagonism and of fraction affected (FA) values, was markedly dependent on the specificity of the combination and on dosing of each agent, as indicated by FA versus Combination Index (CI) plots (Supplementary Figure S2a ). However, the AZD6244-BEZ235-TRAIL and the AZD6244-TRAIL combinations could achieve strong synergism (CIo0.3), with high FA values, in all four cell lines, and the lowest CI values were observed when AZD6244 was used at 0.05 μM (asterisks, Supplementary Figure S2a ). Western blotting analysis confirmed effective inhibition of P-ERK, by AZD6244, and Figure S3 ). Drug interaction analysis was then extended to a panel of 21 melanoma cell lines with distinct susceptibility profiles to the inhibitors and TRAIL. Analysis of the AZD6244-BEZ235-TRAIL combinatorial treatment confirmed a strong synergistic interaction with CIo0.3 and high levels of FA in all AZD6244resistant lines (n = 7) and in 13/14 AZD6244-susceptible lines, when AZD6244 was used at 0.05 μM, irrespective of TRAIL and BEZ235 concentrations (Figure 2a ). In contrast, strong antagonism emerged frequently in most lines at [AZD6244] o0.05 μM and at [BEZ235]o0.02 μM (Supplementary Figure  S4a) . At the most effective AZD6244 dosing, the synergism between target-specific inhibitors and TRAIL was observed not only in cell lines resistant to AZD6244 but even in those with high IC 50 values to BEZ235, or completely resistant to TRAIL, and irrespective of BRAF, NRAS, p53 and PTEN status ( Figure 2 , right hand table). Moreover, increasing doses of BEZ235 and of TRAIL were associated with further improvement in either CI (Figure 2a ) or FA values (Supplementary Figure S5 for box and whiskers plots of FA data). Detailed statistical analysis of FA data ( Supplementary Table S2 ) indicated that significant increase of FA values could be observed when: (a) TRAIL was used at the highest dose (25 ng/ml) in the AZD6244-BEZ235-TRAIL combination compared with 5 and 10 ng/ml; (b) adding BEZ235 to the AZD-TRAIL association; (c) adding TRAIL to the AZD6244-BEZ235 association. In the same panel of cell lines, strong synergism could be observed even by the AZD6244-TRAIL combination, again when AZD6244 was used at 0.05 μM (Figure 2b Figure S6b for box and whiskers plot of FA data). Synergistic interaction of AZD6244-BEZ235-TRAIL and AZD6244-TRAIL associations was confirmed also in melanoma cells freshly isolated from surgical samples (data not shown). Taken together, these results indicated that association of MEK and PI3K/mTOR inhibitors with TRAIL, or MEK blockade with TRAIL, leads to synergistic anti-tumor effects on most melanoma cell lines, even on inhibitor-or TRAIL-resistant ones.
Combinatorial treatments rescue susceptibility of melanoma cells to caspase-dependent apoptosis. To uncover the main biological processes behind the synergistic interactions, we carried out whole genome gene expression analysis of Me13 cells, resistant to TRAIL and poorly responsive to AZD6244, upon treatment with inhibitors and TRAIL. Genes significantly modulated by the AZD6244-BEZ235-TRAIL association, identified by class comparison and visualized by Edwards-VENN diagrams (light blue circles in Supplementary Figure S7a ), 26 were subjected to downstream effects analysis. Significant upregulation of the functions 'cell death' and 'apoptosis' and downregulation of the functions 'tumorigenesis', 'cell migration' and 'proliferation' (Supplementary Figure S7b and Supplementary Table  S3 ) were identified. Analysis of genes modulated by the AZD6244-TRAIL association confirmed enhancement of the functions 'cell death' and 'apoptosis' (Supplementary Figures  S8a and b and Supplementary Table S4 ). By annexin-V/PI flow cytometry assays (Figure 3a ), significantly higher levels of apoptosis, compared with single agents, were observed in 5/8 cell lines by AZD6244-TRAIL or by BEZ235-TRAIL treatments (Po0.01 by analysis of variance (ANOVA) followed by Student-Newman-Keul (SNK) test) and in 8/8 cell lines by the AZD6244-BEZ235-TRAIL combination (Po0.01 in 7/8 lines and Po0.05 in 1/8 lines). Enhanced melanoma apoptosis (Supplementary Figure S9) was also observed by the association of inhibitors with membranebound TRAIL, 27 as well as when TRAIL was associated with different MEK (PD0325901) and mTOR (rapamycin) inhibitors (Supplementary Figure S10 ).
Caspase activation assays indicated significant activation of caspase 3/7, by AZD6244-BEZ235-TRAIL and AZD6244-TRAIL combinations, compared with single agents (Po0.01) and to AZD6244-BEZ235 (Po0.01, Figure 3b ), as well as of 89. 5 3 caspase-8 and 9 (data not shown). A pan caspase inhibitor (z-vad-fmk) completely abolished the increase in apoptosis induced by the addition of TRAIL to the AZD6244-BEZ235 combination, even in TRAIL-resistant (Me13) or in weakly susceptible (Me5) melanomas, but did not impact on cell death promoted by the AZD6244-BEZ235 combination (Figures 3c  and d) . Similar results were observed by the AZD6244-TRAIL combinatorial treatment (Supplementary Figure S11 ). Taken together, these results indicated that co-targeting of MEK and PI3K/mTOR pathways and of the death receptor pathway has synergistic anti-melanoma activity likely mediated by enhanced induction of caspase-dependent apoptosis.
Pro-and anti-apoptotic molecules in the extrinsic and intrinsic apoptosis pathways are modulated by combinatorial treatments. To gain insight into the mechanisms leading to enhanced activation of caspase-dependent apoptosis, we tested whether combinatorial treatments affected expression of pro-and anti-apoptotic molecules in the extrinsic and intrinsic pathways of cell death. Western blotting analysis indicated that the AZD6244-BEZ235-TRAIL combination induced the most marked downregulation of the caspase-8 inhibitor c-FLICE-like inhibitory protein (c-FLIP), with effects seen on both c-FLIP L and/or c-FLIP S (Figure 4a ). This occurred not only in Me41, partially responsive to TRAIL and susceptible to the inhibitors but also in Me13 cells, poorly responsive to AZD6244 and resistant to TRAIL. The same association induced significant caspase-8 cleavage ( Figures  4b and c ). The efficacy of this combinatorial treatment was documented also by analysis of Bcl-2 family members: upregulation of the pro-apoptotic isoforms BIM S and BAXα, 28, 29 downregulation of two isoforms (ps and s) of the Bax inhibitor clusterin 30 (Figure 4d ), and downmodulation of myeloid cell leukemia 1 (Mcl-1) (Supplementary Figure S12 ) and BH3 interacting domain death agonist (BID) (data not shown) were found. In agreement with the known role of these Bcl-2 family members in the mitochondrial pathway of cell death, 31 the AZD6244-BEZ235-TRAIL combination also promoted the strongest increase in mitochondrial depolarization compared with single agents and to the AZD6244-BEZ235 combination (Figures 4e and f) . Enhanced modulation of c-FLIP, and upregulation of BIM S and BAXα, but not of clusterin, compared with single agents ( Supplementary  Figures S13a and b) , as well as caspase-8 cleavage and mitochondrial depolarization (Supplementary Figures  S13c and d) were confirmed also for the AZD6244-TRAIL association.
We then assessed the potential role of several X-linked inhibitor of apoptosis (IAP) family members. Treatment of two melanoma cell lines (Me13 and Me41) with the AZD6244- BEZ235-TRAIL combination induced strong downmodulation of c-IAP1, c-IAP2, XIAP and Apollon compared with the effects of single agents and to AZD6244-BEZ235 treatment (Figure 5a) . Similarly, the AZD6244-TRAIL association was more effective than single agents in downmodulating these IAPs (Supplementary Figure S14) . The giant IAP Apollon was recently shown by us to have a relevant role in suppressing melanoma response to MEK inhibitors and to TRAIL. 27 Silencing experiments, by previously validated siRNA, 27 confirmed the central role of Apollon downmodulation in promoting the apoptotic response of melanoma cells even to these combinatorial treatments. In cells treated with TRAIL only, or with AZD6244-BEZ235, Apollon silencing led to mitochondrial depolarization ( Figure 5b ) and apoptosis levels (Figure 5c ) similar to those found in cells treated with the AZD6244-TRAIL or the AZD6244-BEZ235-TRAIL combination.
Taken together, these results suggest that association of TRAIL with co-targeting of MEK and PI3K/mTOR, or with MEK blockade only, promotes effective melanoma cell death by modulating key molecules involved in regulation of both the extrinsic and intrinsic apoptosis pathways.
Co-targeting of MEK and death receptor pathways has anti-tumor activity in vivo by promotion of melanoma cell death and inhibition of angiogenesis. Our goal was then to verify whether co-targeting of oncogenic and death receptor pathways could exert significant anti-tumor effects in vivo and whether such activity was associated with effects on the tumor microenvironment. To this end, we decided to investigate the effects of treatment with AZD6244 and TRAIL, as both the three-drug (AZD/BEZ/TRAIL) and two-drug (AZD/ TRAIL) associations shared synergistic anti-tumor activity in vitro and similar mechanisms of promotion of apoptosis.
Downstream effect analysis on the set of genes modulated by the AZD6244-TRAIL association (Supplementary Figure  S8a) showed evidence for inhibition of functions associated with migration and proliferation of endothelial cells ( Supplementary Figure S8b and Supplementary Table S4 ), in addition to upregulation of the functions 'cell death and apoptosis'. Upstream regulator analysis predicted a highly significant inhibition of several angiogenesis-related master regulators, including transforming growth factor β1 (TGFβ1), hepatocyte growth factor, epidermal growth factor, v-myc avian myelocytomatosis viral oncogene homolog (Myc), hypoxia inducible factor 1 alpha subunit (HIF1α) and vascular endothelial growth factor alpha (VEGFα) ( Supplementary  Table S5 ), in addition to microphthalmia-associated transcription factor activation, an expected effect of extracellular signalregulated kinase (ERK) pathway inhibition. 32 Protein array experiments on Me13 cells confirmed strong downmodulation of several angiogenesis-related molecules by the AZD6244-TRAIL association, compared with untreated or to AZD6244treated cells (Supplementary Figure S15 ). Western blotting analysis showed a decrease in Myc and HIF1α levels upon treatment of Me13 cells with AZD6244-TRAIL or with AZD6244 only (Supplementary Figure S16a) . Overnight treatment of melanoma cells with AZD6244-TRAIL led to a more pronounced suppression of VEGFα and TGFβ1 secretion, compared with the effects induced by AZD6244 alone (Supplementary Figure S16b ). Control apoptosis assays indicated that the inhibitory effect by Figure S16c) . Moreover, significant inhibition of VEGFα secretion by overnight AZD6244-TRAIL treatment was confirmed in 4 out of the 5 additional melanoma cell lines (Supplementary Figure S16d) . Based on this preliminary in vitro evidence, we then selected a tumor (Me13) resistant to TRAIL and poorly responsive to AZD6244 for in vivo experiments. AZD6244 treatment of severe combined immunodeficiency (SCID) mice, bearing s.c. Me13 xenografts, exerted a moderate but significant tumor inhibition effect, while TRAIL had no impact on tumor growth ( Figure 6a ). However, the AZD6244-TRAIL combination showed a highly significant anti-tumor activity compared not only with TRAIL treatment but also with AZD6244 ( Figure 6a ). Histological analysis of main organs (Supplementary Figure S17a) and monitoring of mice weight (Supplementary Figure S17b) did not indicate any significant toxicity associated with these treatments. Melanoma cells from neoplastic nodules removed at the end of treatment showed enhanced positivity for terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) and cleaved caspase 3, associated with downmodulation of P-ERK and Apollon, in animals treated with the AZD6244-TRAIL association, compared with single treatments (Figure 6b ). These results were consistent with effective inhibition of the ERK pathway and with promotion of melanoma cell death. In addition, the AZD6244-TRAIL combination was more effective than AZD6244 treatment in reducing the expression in vivo, in neoplastic cells, of HIF1α, VEGFα and even of interleukin8, a well-known pro-angiogenic target of HIF-1α (Figure 7a ). Most importantly, neoplastic nodules from animals treated with the AZD6244-TRAIL association showed a markedly reduced density of both large and small blood vessels, as assessed, respectively, by analysis of very wide microscopy fields on hematoxylin and eosin-stained sections (Figure 7b ) and by staining for murine CD31 endothelial cell marker (Figure 7c) .
Taken together, these results indicate that a combinatorial treatment approach that targets at least one relevant melanoma survival pathway (MEK-ERK) and the TRAIL signaling pathway has significant anti-tumor activity in vivo even against a tumor poorly responsive to a MEK inhibitor and completely resistant to TRAIL. Moreover, these results indicate that this strategy acts by both direct anti-tumor effects and by inhibition of angiogenesis.
Discussion
The results of this study indicate that co-targeting of oncogenic and death receptor pathways in melanoma exerts synergistic anti-tumor effects through a direct induction of cell death, by promotion of caspase-dependent apoptosis and through an indirect activity on tumor vasculature. The two effective combinatorial treatments (AZD6244-BEZ235-TRAIL and AZD-TRAIL) were shown to overcome resistance to each agent, and the synergistic drug interaction effects were observed on melanoma cell lines with different genetic background, including mutations of BRAF or NRAS, as well as mutations of p53 and/or PTEN, two genes whose inactivation contributes to melanoma resistance to target therapy. 33, 34 In contrast, the third combinatorial treatment that we investigated (BEZ235-TRAIL) was characterized by marked antagonism and poor fraction affected in most instances, suggesting that inhibition of the PI3K/mTOR pathway can have synergistic anti-melanoma effects with TRAIL only when associated with targeting of the MEK-ERK pathway.
Gene expression experiments coupled to in vitro cell death assays indicated that the anti-tumor effects of the three-and two-drug associations were due to promotion of caspasedependent melanoma cell death. This observation suggested that the combinatorial treatments could effectively counteract distinct apoptosis resistance mechanisms that hinder melanoma response to monotherapy based on TRAIL or targetspecific inhibitors. 9, [35] [36] [37] This hypothesis was confirmed by investigation of several components of the extrinsic and intrinsic pathways of apoptosis. c-FLIP, the main caspase-8 inhibitor, is overexpressed in melanoma lesions 38 and is a main mechanism of melanoma resistance to TRAIL, as indicated by studies where c-FLIP downregulation was sufficient to render TRAIL-R2 + melanoma cells responsive to this death ligand. 39 We found that both the AZD6244-BEZ235-TRAIL and the AZD6244-TRAIL combinations induced strong downmodulation of c-FLIP L and/or c-FLIP s isoforms, associated with caspase-8 activation, compared with single treatments and to the AZD6244-BEZ235 treatment. Moreover, we hypothesized that rescuing the activation of caspase-8 could not be sufficient to explain the overall pro-apoptotic efficacy of the combinatorial treatments but that additional effects on the mitochondrial pathway were likely to occur. In agreement with this hypothesis, we found that co-targeting of oncogenic and death receptor pathways promoted a strong upregulation of pro-apoptotic BIM S and BAXα isoforms, associated with downregulation of clusterin and of Mcl-1. Interestingly, BIM has been recently shown to activate BAX, 40 while clusterin is a known inhibitor of the proapoptotic activity of BAX. 30 Moreover, BIM mediates the apoptotic response to AZD6244 in diffuse large B cell lymphoma 16 and to BEZ235 in KRAS-mutant colorectal cancer cells, 41 while BIM S upregulation has a key role in melanoma apoptosis induced by BRAFV600E inhibitors. 29 Taken together, our results suggest that association of TRAIL with co-targeting of MEK and PI3K/mTOR, or with MEK blockade, triggers a BIM-BAX axis, thus effectively contributing to promotion of mitochondrial depolarization.
We also found that the AZD6244-BEZ235-TRAIL and AZD6244-TRAIL associations influenced the expression of several IAP family members. Overexpression of these proteins contributes to apoptosis resistance in different tumors, including melanoma, 27, 42 by inhibition of both initiator and effector caspases. 43 Interestingly, we found that the combinatorial treatments induced a strong downmodulation of c-IAP1, c-IAP2, XIAP and Apollon, and this may contribute to explain the significant activation of caspase-3/7 that we observed. Moreover, the key role of IAP downmodulation, in the proapoptotic effects of the combinatorial treatments, was confirmed by silencing of Apollon, a IAP whose role in melanoma resistance to a wide range of pro-apoptotic agents we have recently demonstrated. 27 The available evidence on the mechanisms of action, in vivo, of TRAIL and inhibitors as AZD6244 21, 44, 45 led us to hypothesize that their association might have anti-tumor effects not only uniquely exerted through induction of apoptosis but also through inhibition of angiogenesis. Indeed, in SCID mice bearing s.c. melanoma xenografts, we found that the AZD6244-TRAIL association exerted a significant antitumor activity, compared with single treatments, in a TRAILresistant tumor. The combinatorial treatment suppressed not only several pro-angiogenic molecules and, in vivo, promoted melanoma apoptosis, but also significantly affected tumor angiogenesis. The inhibitory effects of AZD6244-TRAIL treatment on master regulators of angiogenesis, such as TGFβ1, HIF1α and Myc, as well as on production of angiogenic molecules as VEGFα, were observed at a time (8-18 h of treatment) when no significant melanoma cell death was yet induced, suggesting that the observed antiangiogenic effect was not simply explained by increased melanoma apoptosis. Moreover, inhibition of the main angiogenesis regulator VEGFα by AZD-TRAIL treatment was observed in several melanoma cell lines, suggesting that this is a general effect of this combinatorial treatment.
In conclusion, the results of this study provide a proof of principle for future combinatorial approaches to melanoma therapy that may overcome intrinsic resistance to single agents 46 and exert relevant effects on the tumor microenvironment.
Materials and Methods
Melanoma cell lines. Melanoma cell lines were established as described 47, 48 from surgical specimens of American Joint Committee on Cancer Stage IIIb to IV melanoma patients not previously subjected to chemotherapy and admitted to Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. All lesions were histologically confirmed to be cutaneous malignant melanomas. The study was conducted according to the Declaration of Helsinki Principles and following institutional guidelines. Molecular and biological features of the cell lines, including susceptibility to TRAIL and to target-specific inhibitors, are listed in Supplementary  Table S1 . Methods for identification of mutations in BRAF, NRAS, PTEN and p53 genes and main molecular features of the cell lines have been previously reported. 27, 42, 48, 49 All cell lines were maintained as described. 47 Treatment of melanoma cells with inhibitors or TRAIL. Cells were treated with different concentrations of AZD6244 (SelleckChem, Houston, TX, USA), BEZ235 (SelleckChem), recombinant human TRAIL (AdipoGen, San Diego, CA, USA) or with combinations of these agents. Treatments were performed in quadruplicates in 96-well flat bottom plates with 200 μl RPMI 1640 (BioWhittaker, VWR International, Radnor, PA, USA) supplemented with 2% fetal calf serum without antibiotics. Cultures were evaluated at 48-72 h as described 27, 42 for cell viability, by the 3-(4,5)dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay. IC 50 values for melanoma response to AZD6244 and BEZ235 were obtained through nonlinear regression analysis (by the PRISM software, Graphpad, La Jolla, CA, USA) of dose-response curves. Data from MTT assays were analyzed for drug interaction by the Chou and Talalay method. 25 Combination indexes and FA values were obtained by the CompuSyn software (ComboSyn Inc., Paramus, NJ, USA).
Antibodies for flow cytometry and western blotting analysis. Flow cytometry and/or western blottig analyses were carried out with antibodies specific for: cleaved caspase 8, livin, clusterin, cIAP-2, BIM, BID, BAX, Mcl-1 and c-Myc (Cell Signaling Technology Inc., Danvers, MA, USA); survivin (Novus Biological, Littleton, CO, USA); c-IAP1 (R&D Systems, Minnneapolis, MN, USA); HIF1α and β-actin (Abcam, Cambridge, UK); Apollon/BIRC6 and XIAP (BD Biosciences, Franklin Lakes, NJ, USA); cFLIP L/S (Alexis Biochemicals, Enzo Life Sciences Inc., Farmingdale, NY, USA); PE-TRAIL-R1/DR4, PE-TRAIL-R2/DR5 (BioLegend, San Diego, CA, USA); and TRAIL-R3/DCR1 and TRAIL-R4/DCR2 (AdipoGen).
Flow cytometry assays. Melanoma apoptosis was assessed by the Annexin V/PI flow cytometry assay as described. 27 Expression of intracellular molecules was evaluated by flow cytometry after cell permeabilization with saponin or methanol, as described. 47 Mitochondrial membrane depolarization was assessed by the fluorescent probe tetramethyl rhodamine ethyl ester (TMRE; Invitrogen, Life Technologies, Grand Island, NY, USA) as described. 27 Flow cytometry experiments were carried out with a Gallios flow cytometer (Beckman Coulter, Inc., Brea, CA, USA). All data were analyzed with the FlowJo software (FlowJo LLC, Ashland, OR, USA).
Western blots. SDS-PAGE was performed using 30-60 μg of protein samples on 7% NuPAGE Tris-Acetate (for Apollon) or 4-12% NuPAGE Bis-Tris polyacrylamide gels (Invitrogen, Life Technologies), as described. 27, 49 Development was performed by the chemiluminescence method with the ECL Western Blotting Detection System (GE Healthcare, Fairfield, CT, USA).
Apoptosis and angiogenesis protein arrays. The Human Angiogenesis Array kit (R&D Systems) was used according to the manufacturer's instructions. Signals on membranes were detected by chemiluminescence and quantitated by densitometric analysis with Quantity One software (Bio-Rad Laboratories Inc., Hercules, CA, USA). Protein expression values were expressed as the percentage of the mean of the relative positive controls, after background subtraction.
Genome-wide expression profiling of melanoma cells treated with target-specific inhibitors and TRAIL. Melanoma cells were treated with AZD6244 (0.1 μM), BEZ235 (0.1 μM) or TRAIL (25 ng/ml) or with their combinations for 8 h. Three biological replicates for each treatment were set up. RNA isolation and processing were performed as described. 27 Single-color hybridization of RNAs was performed on Illumina Bead Chip HumanHT-12_v4 Microarrays (Illumina, San Diego, CA, USA) containing 448 000 transcript probes. The expression profiles have been deposited in NCBI's Gene Expression Omnibus (GEO) with GSE accession number GSE55050. Background correction, filtering of data and quantile normalization were done using the BeadStudio Illumina software. Identification of significantly modulated genes (by BRB array tools vers. 4.3.0), generation of Edwards-VENN diagrams (by the VENNTURE software 26 ) and downstream effects analysis and upstream regulator analysis (by Ingenuity Pathway Analysis, IPA 8.5, www.ingenuity.com) were carried out as described in Supplementary Methods.
Enzymatic activity of caspases and treatment of melanoma cells with caspase inhibitors. Caspase 3/7 activation was evaluated by the MUSE caspase 3/7 kit, specific for the MUSE cell analyzer (Merck Millipore, Billerica, MA, USA). Where mentioned, melanoma cells were preincubated with general caspase inhibitor z-VAD-fmk or control z-FA-fmk (BD Pharmingen, Franklin Lakes, NJ, USA) at 5 μM for 1 h at 37°C before treatment with drugs. Apoptosis was then assessed by the annexin-V/PI flow cytometry assay.
Silencing of Apollon by small interfering RNA (siRNA). Cells were transfected with one of the two previously validated 27 Apollon-specific siRNA (Stealth RNAi siRNA, sequence 5′-GGGCAUGCUGGAAUGUUGACGUUAA-3′, Invitrogen) and corresponding negative control siRNAs according to Lipofectamine RNAiMAX guidelines (Invitrogen) to reach a final siRNA concentration of 75 nmol/l. ELISA. The Quantikine ELISA kit (R&D Systems) for TGFβ1 and VEGFα were used according to the manufacturer's instructions. The optical density of each plate was determined using a microplate reader (Infinite M1000, Tecan Group Ltd., Männedorf, Switzerland).
In vivo treatments. Animal experiments were performed according to the Italian laws (D.L. 116/92 and after additions) and were approved by the institutional Ethical Committee for Animal Experimentation of our Institute and by the Italian Ministry of Health (Project INT_17/2011). Female SCID mice 8-10-weeks old (Charles River Laboratories, Wilmington, MA, USA) were provided with food and water ad libitum. Melanoma cells (Me13) were harvested in exponential growth phase and were injected subcutaneously (5 × 10 6 ) in the left flank of each mouse. When tumors became palpable, mice were randomized into four groups (7 animals/ group). Animals received either vehicle, 25 mg/kg AZD6244 (oral gavage), 30 mg/kg TRAIL (i.p. injection) or a combination of the two drugs, 7 days per week for 2 consecutive weeks. Mice were monitored daily for signs of toxicity and were weighed twice weekly. Tumor size was regularly evaluated by measuring the orthogonal diameters (d and D) and calculating the volumes with the following formula:
Immunohistochemistry. Immunohistochemistry was performed on formalinfixed, paraffin-embedded tissues as described. 27, 42, 47 Tissue sections from melanoma metastases were characterized by staining for TRAIL-R2/DR5 (Sigma-Aldrich, St. Louis, MO, USA). Neoplastic nodules removed from SCID mice at the end of treatment were characterized by staining with mAbs to human pERK, cleaved caspase-3 (Cell Signaling Technology Inc.), Apollon, HIF1α, IL8 (Abcam), VEGFα (Santa Cruz Biotechnology Inc., Dallas, TX, USA), as well as to mouse CD31 (Dianova GmbH, Hamburg, Germany). The extent of apoptosis in neoplastic nodules was evaluated by TUNEL staining (Roche). Images were acquired at × 20 with an Axiovert 100 microscope (Zeiss, Oberkochen, Germany) equipped with a digital camera (AxioCam MrC5, Zeiss).
Statistical analysis. Data from TRAIL susceptibility, TMRE and caspase-8 cleavage assays, as well as the results of drug interaction analyses (combination index values) were clustered by the Cluster 3.0 software (Tokyo, Japan). Significance of different treatments on melanoma apoptosis, caspase activation, mitochondrial depolarization and modulation of apoptosis-and angiogenesis-related molecules was assessed by ANOVA, followed by the SNK multiple comparison test. Correlation of melanoma responsiveness to TRAIL with susceptibility to targetspecific inhibitors or with expression of TRAIL receptors were assessed by Spearman's correlation analysis. In xenograft experiments, comparison of the antitumor activity of different treatments was carried out by mixed effects model ANOVA 50 by the XLSTAT software (Xlstat, Addinsoft's, New York, NY, USA).
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